The cancer patient and cardiology
Por:
Zamorano, JL, Gottfridsson, C, Asteggiano, R, Atar, D, Badimon, L, Bax, JJ, Cardinale, D, Cardone, A, Feijen, EAM, Ferdinandy, P, Lopez-Fernandez, T, Gale, CP, Maduro, JH, Moslehi, J, Omland, T, Gomez, JCP, Scott, J, Suter, TM, Minotti, G
Publicada:
1 dic 2020
Ahead of Print:
1 oct 2020
Resumen:
Advances in cancer treatments have improved clinical outcomes, leading to an increasing population of cancer survivors. However, this success is associated with high rates of short- and long-term cardiovascular (CV) toxicities. The number and variety of cancer drugs and CV toxicity types make long-term care a complex undertaking. This requires a multidisciplinary approach that includes expertise in oncology, cardiology and other related specialties, and has led to the development of the cardio-oncology subspecialty. This paper aims to provide an overview of the main adverse events, risk assessment and risk mitigation strategies, early diagnosis, medical and complementary strategies for prevention and management, and long-term follow-up strategies for patients at risk of cancer therapy-related cardiotoxicities. Research to better define strategies for early identification, follow-up and management is highly necessary. Although the academic cardio-oncology community may be the best vehicle to foster awareness and research in this field, additional stakeholders (industry, government agencies and patient organizations) must be involved to facilitate cross-discipline interactions and help in the design and funding of cardio-oncology trials. The overarching goals of cardio-oncology are to assist clinicians in providing optimal care for patients with cancer and cancer survivors, to provide insight into future areas of research and to search for collaborations with industry, funding bodies and patient advocates. However, many unmet needs remain. This document is the product of brainstorming presentations and active discussions held at the Cardiovascular Round Table workshop organized in January 2020 by the European Society of Cardiology.
Filiaciones:
Zamorano, JL:
Univ Hosp Ramon y Cajal, Dept Cardiol, CiberCV, Madrid, Spain
Gottfridsson, C:
AstraZeneca, Cardiovasc Safety Ctr Excellence, Patient Safety, CMO Org, Gothenburg, Sweden
Asteggiano, R:
Insubria Univ Med, ESC Council Cardiooncol, Varese, Italy
LARC Lab Anal Ric Clin, Turin, Italy
Atar, D:
Oslo Univ Hosp Ulleval, Dept Cardiol, Oslo, Norway
Univ Oslo, Inst Clin Sci, Oslo, Norway
Badimon, L:
Hosp Santa Creu & Sant Pau, ESC Advocacy Comm 2018 2020, CiberCV, Cardiovasc Programme ICCC IR, Barcelona, Spain
Bax, JJ:
Leiden Univ, Dept Cardiol, Med Ctr, Leiden, Netherlands
Cardinale, D:
IRCCS, European Inst Oncol, Cardiooncol Unit, Milan, Italy
Cardone, A:
European Canc Patient Coalit, Brussels, Belgium
Feijen, EAM:
Princess Maxima Ctr Paediat Oncol, Utrecht, Netherlands
Ferdinandy, P:
Semmelweis Univ, Dept Pharmacol & Pharmacotherapy, Budapest, Hungary
Pharmahungary Grp, Szeged, Hungary
Lopez-Fernandez, T:
Univ Hosp La Paz, Dept Cardiol, IdiPAZ, Ciber CV, Madrid, Spain
Gale, CP:
Univ Leeds, Leeds Inst Cardiovasc & Metab Med, Leeds, W Yorkshire, England
Maduro, JH:
Univ Groningen, Univ Med Ctr Groningen, Dept Radiat Oncol, Groningen, Netherlands
Moslehi, J:
Vanderbilt Univ, Med Ctr, Cardiooncol Program, Nashville, TN USA
Omland, T:
Univ Oslo, Akershus Univ Hosp, Dept Cardiol, Oslo, Norway
Gomez, JCP:
Texas Heart Inst, Dept Cardiol, Houston, TX 77025 USA
Baylor Coll Med, Houston, TX 77030 USA
Scott, J:
Mem Sloan Kettering Canc Ctr, Exercise Oncol Res Program, 1275 York Ave, New York, NY 10021 USA
Suter, TM:
Bern Univ Hosp, Dept Cardiol, Inselspital, Bern, Switzerland
Minotti, G:
Campus Biomed Univ Sch Med, Rome, Italy
Bronze
|